Open data policies in proteomics are starting to revolutionise the field
Posted: 28 February 2019 | Juan Antonio Vizcaíno - European Bioinformatics Institute and Wellcome Trust Genome Campus | No comments yet
High-throughput mass spectrometry (MS)-based proteomics approaches have developed enormously in recent years and are continuing to do so. The current trend sees proteomics being used by academia and industry to tackle intricate biological questions, often in conjunction with other high-throughput “omics” disciplines such as genomics, transcriptomics and metabolomics. Within the pharmaceutical industry, proteomics has proved to be a valuable platform for protein-based biomarker discovery as well as for target identification and validation.